您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2018 - 11 - 09
点击次数: 0
所属职位: 董事长
所属公司: 方恩(天津)医药发展有限公司
个人简介:
Dr. Dan Zhang is the Executive Chairman of Fountain Medical Development Ltd, a clinical CRO with 1700 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia & USA.Dr. Zhang was the Head of Clinical Development and was the Head of Safety Assessment at Sigma-Tau Research Inc-leading Italian Pharmaceutical Company, He was the vice president at the Quintiles Transnational Corp., the world largest clinical CRO,  and Chairman of Quintiles Medical Development (Shanghai) Company Ltd.Dr. Zhang is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration (CFDA). He is a member of ICH E19 Expert Working Group. He is also chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. Dr. Zhang is also a senior consultant for the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China, and was the secretary-general of the Association of “Thousand Talent” Expert from 2011-2017. Dr. Zhang was the former board of directors for the Sino-American Pharmaceutical Association (SAPA) and was the former president of Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang is chairing the government relationship committee of Bayhelix-an organization hosting senior executives from life-science organizations in USA and China.Dr. Zhang received his pre-med training from Peking University and received M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.
发布时间: 2018 - 11 - 14
点击次数: 0
所属职位: 运营合伙人
所属公司: 鼎丰生科资本
个人简介:
Ben joined Pivotal Bioventure Partners as an Operating Partner from April, 2017. Ben has overall 24+ years’ extensive experience of global pharmaceutical R&D and business development in addition to building small biotech and CRO.  Before joining us, Dr. Ben Ni was CEO of iPharma (H.K) Ltd  (and i-Bridge operating partner) and from 2010-2017, Ben was the Head of External Innovation & Partnering, Strategy and Business Development, responsible for Sanofi licensing, transaction & partnering, from Asia pacific region. Since 1994, Ben worked as member of senior management team  in several global healthcare/pharmaceutical companies such as Eli Lilly/US (Action Group Chair), Covance (General Manager, Greater China), GSK (Neurodegenerative Disease Center, Global head ) where Ben has the proven track record of transitioning compounds from drug discovery/research phase into clinical development in several therapeutic areas and  plays pivotal roles in global R&D, Clinical service management in China. His value-add lies in broad and diverse scientific and business management expertise/knowledge in multi sectors of global healthcare industry under multi-culture environment in US and Asia.Ben has 40 publications in top international journals including Science, PNAS, five book chapters and four granted US patents. Ben is also adjunct professor in several universities in US and Singapore. Ben has been invited speaker in 60 international conferences and professional seminars.Ben holds a Ph. D in molecular pharmacology from University of Toronto under fellowship and post-doctoral fellowship in Clinical Pharmacology from National Institute of Health.
发布时间: 2018 - 11 - 14
点击次数: 0
所属职位: 创始人兼CEO
所属公司: 上海岸迈生物科技有限公司
个人简介:
吴辰冰博士从美国佐治亚大学生物化学系获得生物化学与分子生物学博士后,进入美国哈佛医学院进行博士后研究,获得美国癌症研究中心的研究基金,主要从事分子免疫学的研究,在揭示XLP疾病的机理方面有重要突破。后来进入雅培制药公司生物研究中心,从事治疗性抗体的研究与开发十多年,带领多个项目从早期研究开始成功进入到临床申报。吴博士长期从事分子免疫及抗体药物研究工作,有多篇首席作者论文发表在Nature Immunology和Nature Biotechnology等国际一流学术刊物,并有多项国际专利授权和50多项国际专利申请。 之后吴博士回国加入上海睿智化学研究有限公司,建立了一个全方位的治疗性抗体研发平台,并借此与国内外生物医药企业广泛合作,成功地开发出一些有影响力的创新抗体药物。吴博士于2013年加盟上海中信国健药业股份有限公司,担任首席科学官兼研究院院长,主要致力于完善研发梯队,建立技术平台,充实研发管线,制定研发策略,并入选浦东百人。2016年5月吴博士开始担任上海岸迈生物科技有限公司总裁,主要进行新一代生物大分子的技术开发及产品研发,带领团队开发出新一代的双特异性抗体平台技术“FIT-Ig”,目前已有多种由该技术开发出来的新型抗体进入临床申报阶段,未来将致力于建立一个创新型国际化的生物制药企业。 2017年初岸迈生物成功完成2500万美元A轮融资,其首个抗肿瘤产品获十三五重大专项立项,并荣获中国创新创业大赛生物组(初创企业)行业全国总决赛冠军。
发布时间: 2018 - 11 - 14
点击次数: 0
所属职位: 首席执行官、创始人,首席科学官
所属公司: 华领医药
个人简介:
陈力博士,华领医药有限公司董事、首席执行官、创始人,首席科学官。陈力博士曾任罗氏研发中国有限公司首席科学官,拥有20多年新药研发创新及管理经验。陈力博士于2011年成立华领医药,以“患者为先、创新为本、良药为民”为宗旨,运用“中西合璧、联合创新”的新药研发运营模式和“高标准、高质量、创造高价值”的经营理念,在5年内华领医药的糖尿病全球原创新药HMS5552成功取得中美临床试验批件、完成四个临床I期和临床II期POC试验,并在2017年全球率先启动同类产品III期临床试验和药品上市计划,实现全球首创、中国首发。在此期间,成功完成2亿美元融资和中国新药创新公司建设。陈力博士1992年毕业于爱荷华州立大学,获博士学位,同年加入罗氏美国研发中心。在罗氏陈博士从一名药物化学资深研究员成长为高通量技术部主任,2004年回中国建立罗氏中国研发中心,任首席科学官和董事。陈力博士是35件授权专利发明人和17件专利申请发明人, 并发表60多篇科学论文。
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务